Summary & Overview
HCPCS J3372: Vancomycin HCl (Xellia) Injection, 500 mg
HCPCS Level II code J3372 denotes a 500 mg injection of vancomycin hydrochloride (Xellia) that is identified as not therapeutically equivalent to J3370. This designation matters nationally for accurate drug identification, reimbursement distinctions, and inventory management in facilities that administer parenteral antibiotics. Hospitals, infusion centers, and outpatient settings must code precisely to reflect the specific vancomycin product used.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for vancomycin injections, coding implications of using a brand-specific HCPCS Level II drug code, and what to expect in payer coverage terminology. The publication summarizes national benchmarks and common billing considerations, highlights policy and coding nuances tied to non-equivalent drug entries, and outlines settings where the code is most often reported.
The piece provides actionable reference material for billing teams, pharmacy procurement, and revenue cycle staff: how J3372 is described, where it is typically administered, and which major payers are commonly referenced in coverage discussions. Data gaps in the input are noted where applicable as "Data not available in the input."
Billing Code Overview
HCPCS Level II code J3372 represents an injectable formulation of vancomycin hydrochloride (Xellia), 500 mg, explicitly noted as not therapeutically equivalent to J3370. The code describes a parenteral antimicrobial agent used for treatment of serious gram-positive infections where vancomycin is indicated.
Service Type: Injection, antimicrobial/antibiotic therapy
Typical Site of Service: Hospital inpatient or outpatient infusion center, ambulatory surgical center, or other clinical infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old hospitalized patient with severe methicillin-resistant Staphylococcus aureus (MRSA) bacteremia develops clinical signs requiring intravenous glycopeptide therapy. The physician orders J3372 (Injection, vancomycin hcl (xellia), not therapeutically equivalent to J3370, 500 mg) to provide a measured vancomycin product that is not therapeutically equivalent to the reference HCPCS J3370. Typical workflow: pharmacy validates the order, confirms dose based on weight and renal function, prepares the preservative-free injectable vial or bag, and the infusion nurse administers per institution protocol. Therapeutic drug monitoring is performed with trough or AUC-guided levels and renal function is monitored throughout therapy. Common sites of service include inpatient hospital (acute care), observation, and hospital outpatient infusion center. Clinical scenarios include severe skin and soft tissue infections, bone and joint infections (osteomyelitis), endocarditis, and nosocomial pneumonia due to gram-positive organisms where vancomycin is indicated and a specific manufacturer-sourced product (J3372) is requested or required due to formulary, supply, or sensitivity considerations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|